Related Experiment Video

Updated: Jun 8, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Tetrahydrobiopterin therapy for phenylketonuria in infants and young children

Barbara K Burton1, Darius J Adams, Dorothy K Grange

  • 1Department of Pediatrics, Northwestern University Feinberg School of Medicine and PKU Clinic, Children's Memorial Hospital, Chicago, IL 60614-3363, USA. bburton@childrensmemorial.org

The Journal of Pediatrics
|October 2, 2010
PubMed

Insights

Sapropterin therapy is safe and effective for managing phenylketonuria (PKU) in young children. This treatment, combined with a restricted diet, helps control blood phenylalanine levels for better neurocognitive development.

Area of Science:

  • Biochemistry
  • Pediatric Medicine
  • Metabolic Disorders

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring strict dietary management.
  • Maintaining low blood phenylalanine (Phe) levels is crucial for neurocognitive development in young children.
  • Sapropterin is a pharmacological approach to managing PKU.

Observation:

  • This study reviewed six case reports of infants and children under 4 years old with PKU treated with sapropterin.
  • Patient selection, treatment administration, response evaluation, and side effect management were described.
  • Blood Phe levels and dietary Phe tolerance were monitored.

Findings:

  • Sapropterin treatment was found to be safe and well-tolerated in this pediatric cohort.
  • Blood Phe levels were reduced in patients responsive to sapropterin.
  • Increased dietary Phe tolerance was observed in some patients, particularly those with well-controlled baseline Phe levels.

Implications:

  • Sapropterin, in conjunction with a Phe-restricted diet, can effectively manage blood Phe levels in responsive young PKU patients.
  • Maintaining blood Phe below 360 μmol/L is vital for normal neurocognitive and behavioral function.
  • These findings support sapropterin as a therapeutic option for early intervention in PKU management.
Abstract

More Related Videos

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...